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Is Electricity Useful
When the Pump Is Failing?
More Data Urgently Needed*
Rachel Lampert, MD
New Haven, Connecticut
The benefit of prophylactic implantation of an implantable
cardioverter-defibrillator (ICD) or cardiac resynchroniza-
tion therapy (CRT) ICD (CRT-D) in improving mortality
in patients with heart failure has been firmly established by
multiple randomized controlled trials (RCT) (1–4). How-
ever, it has also been well documented that patients receiv-
ing ICDs in the “real world” are older and sicker, with
higher prevalences of diabetes, hypertension, and atrial
fibrillation than are those enrolled in the landmark RCTs
(1,3,5). It is an inherent limitation of RCTs that strict entry
criteria limit “real-world” generalizability (6), and attempt-
ing to understand whether the findings of the RCTs can be
extrapolated to these sicker patients is an important endeavor.
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Several previous studies of varying design have suggested that
overall the benefit of the ICD for primary prevention of sudden
cardiac death in patients in the real world is similar to that in
the trials. Using administrative data from the Medicare data-
base, Groeneveld et al. (7) compared 7,125 ICD recipients to
a propensity-score matched group, finding a hazard ratio (HR)
for mortality of 0.62 with the ICD. In a population-based
study, Parkash et al. (8) compared outcomes between all
patients receiving an ICD in Nova Scotia and comparable
patients in a province-wide database. They found a dramatic
survival benefit from the ICD, with an unadjusted HR for
mortality of 0.46, going to 0.55 to 0.59 after multivariable and
propensity analyses. In the most rigorous study to date of
real-world benefit, Al-Khatib et al. (9) used patient-level data
to compare mortality between ICD recipients in the NCDR
(National Cardiovascular Data Registry) meeting criteria for
MADIT-II (Multicenter Automatic Defibrillator Implanta-
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Medtronic.tion Trial II) (3) or SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial) (1) and the participants in those trials,
looking at both ICD recipients and those randomized to
standard-of-care medical therapy. Despite the fact that the
NCDR patients were older and had greater comorbidities, the
mortality in the NCDR patients was similar to ICD recipients
in the trials, and significantly better than that in the trial
control groups (HR: 0.73; 95% confidence interval [CI]: 0.59
to 0.92; p  0.007 for the MADIT-II comparison, and HR:
0.82; 95% CI, 0.7 to 0.96; p  0.01 for the SCD-HeFT
comparison).
The study by Chen et al. (10) in this issue of the
Journal, analyzing data from the Centers for Medicare
and Medicaid Services subset of the NCDR ICD regis-
try, adds to the characterization of real-world ICD
recipients as sicker overall than were participants in
MADIT-II and SCD-HeFT, with a higher burden of chronic
heart failure, with 15% having had 1 heart failure admission
within the previous year and 5% having had 2 or more. They
also describe a high burden of acute heart failure, with 31% in
the hospital 2 or more days before the implantation, suggesting
a nonelective implantation. The higher the burden of both
chronic and acute heart failure, the higher the mortality in the
1, 2, and 3 years after ICD implantation. They also contrast
the mortality of this Medicare cohort with the published
data on mortality in the ICD groups of MADIT-II and
SCD-HeFT, noting higher mortality in the NCDR sub-
groups of patients with higher heart failure burden com-
pared with ICD recipients in these trials.
It is important to note, however, that 48% of the patients
analyzed were recipients of CRT-D devices. Whereas pa-
tients in SCD-HeFT and MADIT-II had stable heart
failure, those in COMPANION (Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure), the
pivotal study demonstrating CRT-D benefit, had class III
or IV congestive heart failure (CHF), and at least 1 previous
heart failure hospitalization in the past year was required for
inclusion in that trial (4). Only 5% of this Medicare
population had a greater burden of CHF, as defined here
based on previous hospitalizations, than was required for the
COMPANION participants. Similarly, with the exception
of the very highest heart failure burden groups, the mortal-
ities are more similar to those of COMPANION CRT-D
recipients. The combining of ICD and CRT-D patients in
the current analysis makes contrast with previous study
populations difficult.
Despite this limitation, the very high mortality at 1 year
in the highest-heart-failure burden groups raises the pro-
vocative question: Does the benefit of the ICD seen in the
RCTs extend to those with significantly higher heart failure
burden than trial participants, such as the 5% with2 CHF
admissions in the preceding year or 6% with a prolonged
preceding hospital stay? Without comparison against a
group of comparable patients who did not receive an ICD,
this study cannot in itself answer this important question.
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Post-ICD Mortality in CHF May 28, 2013:2151–2Although those with a high burden of heart failure are more
likely to die after an ICD than are those with a low burden,
the question most relevant to patient care is whether or not
patients with a high burden of heart failure are less likely to
die with an ICD than they are without one, and the
question cannot be determined by the data here. As dis-
cussed by Chen et al. (10), there are theoretic reasons why
patients with severe CHF might not benefit from an ICD,
as the percentage of death that is sudden decreases as heart
failure severity increases. In a subanalysis of MADIT-II
(11), among those receiving dual-chamber (but not single-
chamber) devices, the ICD no longer conferred benefit after
a CHF hospitalization. To what extent those findings could
be extrapolated to all-comers regarding pre-implant hospi-
talization, and to CRT candidates, is unknown. As the
investigators note, given the high competing mortality
demonstrated in the current study in patients with high
burden of heart failure, further research is needed to
determine whether ICD implantation during a prolonged
CHF hospitalization or following multiple hospital admis-
sions will confer survival benefit.
Identification of subgroups in whom the ICD will not
confer benefit, particularly due to competing early mortality,
is an important endeavor. Whereas ICD patients for the
most part enjoy quality of life similar to that of other cardiac
patients (12), shocks (13), particularly at the end of life (14),
do affect quality of life for patients and families. Whereas
ICD deactivation can avert shocks at the end of life (15),
implantation with deactivation within a year is not of benefit
either to patients or a cost-conscious society. It is often
difficult to predict impending death in CHF, which waxes
and wanes, underscored by the fact that many patients in
this cohort had had 3 or more CHF hospitalizations in the
preceding year, which is aggressive care in itself. The very
high mortality documented here emphasizes the importance
of integration of palliative care, underused in advanced heart
failure (16), and of careful consideration of aggressive
therapies for those with highest burden of CHF.
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